Drug Eluting Balloon Market Advances with Rising Cardiovascular Disease Burden and Minimally Invasive Treatment Adoption

The Global Drug Eluting Balloon (DEB) Market is experiencing robust growth as healthcare providers increasingly adopt minimally invasive vascular intervention technologies for the treatment of coronary and peripheral artery diseases. According to Maximize Market Research, the Drug Eluting Balloon Market was valued at USD 0.82 Billion in 2023 and is projected to reach USD 1.54 Billion by 2030, growing at a CAGR of 9.4% during the forecast period.

The market is being driven by the rising prevalence of cardiovascular diseases, increasing incidence of peripheral artery disease (PAD), and growing preference for minimally invasive procedures that reduce complications associated with permanent implants. Drug eluting balloons deliver antiproliferative drugs directly to diseased vessels, helping prevent restenosis while avoiding the need for additional stent placement. Growing awareness among physicians regarding the clinical benefits of DEB therapy, coupled with technological advancements in drug delivery mechanisms and balloon catheter designs, is creating substantial market opportunities. Increasing healthcare expenditure, expanding access to advanced cardiovascular treatments, and favorable clinical outcomes are expected to support long-term market growth.

* Read Expert Industry Analysis: https://www.maximizemarketresearch.com/request-sample/40237/ 

U.S. Market Trends and Investments

The United States remains a major contributor to the global drug eluting balloon market, supported by a large cardiovascular patient population and advanced interventional cardiology infrastructure. During 2025, healthcare providers increased investments in next-generation vascular intervention technologies aimed at improving patient outcomes and reducing repeat procedures. Medical device manufacturers have continued expanding research programs focused on enhanced drug coatings, improved balloon platforms, and advanced catheter delivery systems. Growing adoption of outpatient vascular procedures and increasing emphasis on minimally invasive treatments have further strengthened market demand. Additionally, ongoing clinical trials evaluating new drug formulations and broader indications for DEB therapy are expected to create significant growth opportunities within the U.S. healthcare system.

Market Segmentation Analysis

According to the Maximize Market Research report, the Coronary Drug Eluting Balloon segment holds the largest share of the global market. The segment's dominance is primarily attributed to the high prevalence of coronary artery disease and the growing adoption of minimally invasive treatment options in interventional cardiology.

By application, the Coronary Artery Disease segment accounts for the largest market share due to increasing cardiovascular disease incidence worldwide and the proven effectiveness of drug eluting balloon therapy in reducing vessel re-narrowing. Hospitals continue to represent the largest end-user segment owing to the availability of advanced cardiac catheterization laboratories and specialized cardiovascular care facilities.

Drug Eluting Balloon Market, Key players are:
1. Medtronic, Inc.
2. Becton, Dickinson and Company
3. Boston Scientific Corporation
4. Cook Medical Incorporated
5. Braun Melsungen AG
6. Koninklijke Philips N.V.
7. Opto Circuits (India) Limited
8. Terumo Corporation
9. Surmodics, Inc.
10. Biotronik, Inc.
11. Concept Medical Inc.
12. BIOTRONIK SE & Co. KG
13. Innvolution Healthcare Pvt. Ltd.
14. Medtronic plc
15. Eurocor GmbH
16. C.R. Bard
17. Aachen Resonance GmbH

Competitive Analysis

B. Braun Melsungen AG

B. Braun remains one of the leading participants in the drug eluting balloon market through its advanced vascular intervention portfolio. The company continues investing in innovative balloon catheter technologies and enhanced drug delivery systems designed to improve procedural success and patient outcomes.

Medtronic plc

Medtronic has strengthened its position in the cardiovascular device sector through ongoing investments in minimally invasive treatment technologies. The company continues focusing on research initiatives that improve vascular intervention efficiency and expand treatment options for complex cardiovascular conditions.

Boston Scientific Corporation

Boston Scientific continues to invest heavily in interventional cardiology innovation. Recent product development efforts emphasize advanced catheter technologies, improved deliverability, and enhanced drug transfer capabilities that support broader adoption of drug eluting balloon therapies.

Becton, Dickinson and Company (BD)

BD remains a significant player in vascular intervention technologies. The company has expanded investments in peripheral vascular treatment solutions and advanced catheter-based therapies designed to improve clinical outcomes and physician workflow efficiency.

Koninklijke Philips N.V.

Philips continues to strengthen its cardiovascular care portfolio through investments in image-guided therapy systems and integrated treatment solutions. The company's focus on advanced imaging technologies supports more precise and effective drug eluting balloon procedures.

* Read Expert Industry Analysis: https://www.maximizemarketresearch.com/request-sample/40237/ 

Regional Analysis

United States

The United States accounts for a substantial share of the global drug eluting balloon market due to high cardiovascular disease prevalence, advanced healthcare infrastructure, and strong adoption of minimally invasive treatment procedures. Continuous investments in cardiovascular innovation contribute significantly to market growth.

United Kingdom

The UK market is supported by increasing awareness of vascular disease management and continued investments in advanced interventional cardiology services through the National Health Service (NHS). Growing emphasis on minimally invasive treatments is driving adoption.

Germany

Germany represents one of Europe's largest markets for drug eluting balloons due to its advanced healthcare system and strong cardiovascular treatment capabilities. Favorable reimbursement policies and high utilization of innovative medical devices contribute to market expansion.

France

France is experiencing growing demand for advanced vascular intervention technologies supported by healthcare modernization initiatives and increasing cardiovascular disease management programs. Hospital investments in innovative treatment options continue to support growth.

Japan

Japan's market growth is driven by an aging population, rising incidence of cardiovascular diseases, and strong adoption of advanced medical technologies. Continuous innovation in interventional cardiology supports increasing demand for drug eluting balloon therapies.

China

China is emerging as one of the fastest-growing markets due to expanding healthcare infrastructure, rising cardiovascular disease burden, and increasing access to advanced medical treatments. Government initiatives supporting healthcare modernization are accelerating market development.

Conclusion

The global drug eluting balloon market is positioned for strong growth as healthcare systems increasingly prioritize minimally invasive cardiovascular treatments that improve long-term patient outcomes. Rising prevalence of coronary and peripheral artery diseases, coupled with continuous advancements in drug delivery technologies, will remain the primary drivers of market expansion. Future opportunities are expected to emerge from next-generation drug coatings, broader clinical applications, and expanding adoption across emerging healthcare markets. Companies that invest in innovation, clinical evidence generation, and advanced catheter technologies are likely to strengthen their competitive position in the evolving cardiovascular treatment landscape.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com